Results 211 to 220 of about 1,952,521 (307)

Analysis of hemorrhagic transformation and intracerebral hemorrhage under combination therapy with alteplase and antiplatelets or anticoagulants, using the Japanese Adverse Drug Event Report database. [PDF]

PLoS One
Nakai T, Koseki T, Nakao H, Kato K, Takahashi K, Yamada S, Matsumoto S.   +6 more
europepmc   +1 more source

Effects of Non‐Aspirin Nonsteroidal Anti‐Inflammatory Drugs on Acute Intracerebral Hemorrhage

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Despite celecoxib, a cyclooxygenase‐2 inhibitor, promoting functional recovery from intracerebral hemorrhage (ICH) by reducing inflammation‐mediated perihematomal edema in rat models, the evidence of its effects on patient outcomes remains limited.
Shin‐Joe Yeh, Sung‐Chun Tang, Li‐Kai Tsai, Jiann‐Shing Jeng   +3 more
wiley   +1 more source

Organoid models established from primary tumors and patient-derived xenograft tumors reflect platinum sensitivity of ovarian cancer patients. [PDF]

BMC Cancer
Nikeghbal P, Zamanian D, Burke D, Steinkamp MP.   +3 more
europepmc   +1 more source

SYHA1813, A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Recurrent high‐grade gliomas have a poor prognosis and limited therapeutic options. This study aimed to evaluate the safety and efficacy of SYHA1813, a dual inhibitor of VEGFR and CSF1R, in patients with recurrent high‐grade gliomas.
Zhuang Kang, Shenglan Li, Liang Wang, Qianxue Chen, Weiguo Hu, Ting Lei, Ying Mao, Jing Zhang, Xiaojun Xiang, Qiming Wang, Zhengwen He, Tao Sun, Yulei Wang, Mengqian Huang, Rong Zhang, Feng Chen, Wenbin Li   +16 more
wiley   +1 more source

Dual molecular therapy targeting tumor cell heterogeneity improves therapeutic efficacy in glioblastoma. [PDF]

iScience
Hirano S, Uneda A, Otani Y, Suruga Y, Imoto R, Hokama M, Umeda T, Ikemachi R, Nishigaki S, Tsuboi N, Makino K, Kemmotsu N, Kegoya Y, Matsumoto Y, Tomita Y, Shimazu Y, Ishida J, Fujii K, Wakimoto H, Tanaka S, Date I.   +20 more
europepmc   +1 more source

Genetic Modifiers of Parkinson's Disease: A Case–Control Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To examine the associations of LRRK2 p.G2019S, GBA1 p.N409S, polygenic risk scores (PRS), and APOE E4 on PD penetrance, risk, and symptoms. Methods We conducted a US‐based observational case–control study using data from the 23andMe Inc. and Fox Insight Genetic Substudy (FIGS) databases.
Matthew J. Kmiecik, Michael V. Holmes, Pierre Fontanillas, Giulietta M. Riboldi, Ruth B. Schneider, Jingchunzi Shi, Anna Guan, Susana Tat, Steven Micheletti, Keaton Stagaman, Josh Gottesman, David A. Hinds, Joyce Y. Tung, 23andMe Research Team, Stella Aslibekyan, Lucy Norcliffe‐Kaufmann   +15 more
wiley   +1 more source

Tau biology, biomarkers, and therapeutics. [PDF]

Alzheimers Dement (N Y)
Frost B, Kolb H, Algeciras-Schimnich A, Betthauser TJ, DeVos S, Edelmayer RM, Elwood F, Fleisher AS, Henley D, Horie K, Hyman B, Kreisl WC, Kulic L, Leuzy A, Palma JA, Parmentier-Batteur S, Patru MM, Rabinovici GD, Reyderman L, Sperling RA, Van Der Geyten S, Wildsmith KR, Mahinrad S, Carrillo MC, Weber CJ.   +24 more
europepmc   +1 more source

Assessing a Mitochondrial Disease Treatment via a Novel Statistical Technique for Accelerometer Data

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Therapeutic development for mitochondrial diseases, rare genetic disorders with pathogenic defects of oxidative phosphorylation, is hindered by unsatisfactory outcome measures. To address this problem, we provide the first clinical application of a novel, bias‐adjusted outcome measure of acceleration across a range of subjects ...
Ian W. McKeague, Kristin Engelstad, Yue Ge, Amber Tucker, Shufang Li, Jasim Uddin, Ziwei Zhao, John L. P. Thompson, Michio Hirano   +8 more
wiley   +1 more source

Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis.

J Clin Endocrinol Metab
Bahl S, Taylor PN, Premawardhana LD, Stedman M, Heald A, Dayan CM, Okosieme OE.   +6 more
europepmc   +1 more source

The advantages and challenges of sorafenib combination therapy: Drug resistance, toxicity and future directions (Review). [PDF]

Oncol Lett
Wei M, Cao Z, Dong L, Wang W, Wei M, Ji L, Duan L, Sun H, Zheng M.   +8 more
europepmc   +1 more source